Back to Search
Start Over
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab.
- Source :
-
Modern rheumatology [Mod Rheumatol] 2013 Jul; Vol. 23 (4), pp. 827-31. Date of Electronic Publication: 2012 Jul 11. - Publication Year :
- 2013
-
Abstract
- Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthly administration of the anti-IL-6 receptor antibody tocilizumab. The treatment rapidly reduced the elevated numbers of plasmablasts and anti-AQP4 autoantibodies in the patient. Furthermore, neuropathic pain and disability scores gradually improved. Tocilizumab may be considered as a therapeutic option for NMO.
Details
- Language :
- English
- ISSN :
- 1439-7609
- Volume :
- 23
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Modern rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 22782533
- Full Text :
- https://doi.org/10.1007/s10165-012-0715-9